Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Making use of the tumoral TGFB1 signaling network in the context of MSC-mediated NIS gene delivery is a promising approach to foster tumor stroma-selectivity of NIS transgene expression and tailor NIS-based gene therapy to TGFB1-rich tumor environments.
|
30121623 |
2019 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Increased expression of the cell surface receptor c-Met, the glucose transporter GLUT-1 and the sodium iodide symporter lead to tumour growth, angiogenesis and cell migration.
|
30819129 |
2019 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Recent studies have described important roles for the sodium iodide symporter (NIS) in tumor behavior.
|
30191346 |
2019 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Combination of EBRT and SMAD-NIS-MSC-mediated <sup>131</sup>I therapy resulted in a significantly improved delay in tumor growth and prolonged survival in therapy mice as compared with the combined therapy using CMV-NIS-MSCs or to control groups receiving EBRT or saline only, or EBRT together with SMAD-NIS-MSCs and saline applications.
|
31196853 |
2019 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Ultimately, combining BLI and NIS imaging represented a significant enhancement over traditional BLI, providing more information about tumor size and location.
|
30674994 |
2019 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In conclusion, the dual-targeting approach highlights the benefits of a bifunctional strategy for a future clinical translation of the bioimaging-based NIS-mediated radiotherapy allowing efficient targeting of heterogeneic tumors with variable receptor expression levels.
|
30683895 |
2019 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Active MSC recruitment into the tumor stroma was confirmed using NIS immunohistochemistry (IHC).
|
30224540 |
2019 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Synthesis and evaluation of <sup>18</sup>F-hexafluorophosphate as a novel PET probe for imaging of sodium/iodide symporter in a murine C6-glioma tumor model.
|
29198608 |
2018 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Furthermore, we evaluated enhancement of NIS promoter and therapeutic efficacy of RAI in ATC tumour xenograft mice.
|
29467951 |
2018 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We aimed to evaluate if NIS expression in thyroid primary tumors would be helpful in predicting tumor behavior, response to therapy and prognosis.
|
29298843 |
2018 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Further clinical evaluation as a PET tracer for imaging thyroid pathophysiology and human sodium/iodide symporter expressing neoplasms is highly warranted.
|
29356744 |
2018 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
NIS repression by activated p53 is further confirmed by non-invasive bioluminescence imaging in live cell and orthotropic tumor model.
|
28528452 |
2017 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
These results clearly demonstrate that systemic in vivo NIS gene transfer using nanoparticle vectors coupled to B6 tumor targeting ligand is capable of inducing tumor-specific radioiodide uptake.
|
28423213 |
2017 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Oncolytic VSV engineered to express interferon-beta (IFNβ) and the sodium iodide symporter (NIS), VSV-IFNβ-NIS, has been shown to be a potent new therapeutic agent inducing rapid and durable tumor remission following systemic therapy in preclinical mouse models.
|
28514874 |
2017 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Enhancing Expression of Functional Human Sodium Iodide Symporter and Somatostatin Receptor in Recombinant Oncolytic Vaccinia Virus for In Vivo Imaging of Tumors.
|
27635026 |
2017 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Administration of a therapeutic dose of 131I in mice treated with NIS-transfected MSCs resulted in delayed tumor growth and reduced tumor perfusion, as shown by contrast-enhanced sonography, and significantly prolonged survival of mice bearing orthotopic HCC tumors.
|
27458162 |
2016 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemical staining showed that HeLa-TERTNIS xenograft tumors expressed higher levels of NIS and caspase-3 and lower levels of Ki-67 than HeLa xenograft tumors.
|
27573304 |
2016 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Oncolytic VSV-IFNβ-NIS is selectively destructive to tumors.
|
27532609 |
2016 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Imaging for NIS expression showed robust virus infection within the tumors.
|
26712908 |
2016 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
131I treatment reduced tumor sizes of hNIS- and opt-hNIS-expressing tumors to 0.57- and 0.27- fold, respectively, compared to their sizes before therapy, suggesting an improved therapeutic effect of opt-hNIS.
|
25553100 |
2015 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Local administration of MV-NIS into MPNST-derived tumors resulted in significant regression of tumor and improved survival.
|
25843626 |
2015 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In xenograft tumor models, uptake of (99m)TcO4 (-) was obviously higher in the hNIS and rNIS groups compared with controls.
|
26115738 |
2015 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
To expand the potential range of tumor targets, we investigated the biodistribution and tumor recruitment of MSCs transfected with NIS under control of the RANTES/CCL5 promoter (RANTES-NIS-MSC) in a colon cancer liver metastasis mouse model established by intrasplenic injection of the human colon cancer cell line LS174t.
|
25745085 |
2015 |
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The NGS data revealed the coexisting of a well-characterized loss-of-function TP53 R248Q mutation and a putative gain-of-function mutation of TSHR L272V, which was suggested by the overexpression of thyroglobulin and SLC5A5 (NIS) genes in this tumor.
|
26260781 |
2015 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Given the recent progress in the study of NIS regulation as molecular basis for new therapeutic approaches in extrathyroidal cancers, particular attention is given to studies regarding the relationship between NIS and clinical-pathological aspects of the tumors and the regulation of NIS expression in the experimental models.
|
24884806 |
2014 |